Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) - USD ($)		3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Oct. 05, 2023	Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax		$ 334,617	$ 978,052
Alphazyme [Member]
Proceeds from Sale, Maturity and Collection of Investments		61,000		$ 1,300,000
Alphazyme [Member]
Ownership Percentage						1.99%
Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		334,617	933,934
Inzymes Agreement APS [Member]
Non-refundable Upfront Payment, Received					$ 600,000
Revenue from Contract with Customer, Excluding Assessed Tax		52,000
A Global Food Ingredient Company [Member] \| Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 0	339,000
Janssen Pharmaceutical Companies [Member]
Deferred License Revenue	$ 176,000		44,000
Deferred License Revenue, Net of Current Portion	$ 132,000		132,000
Janssen Pharmaceutical Companies [Member] \| Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax			$ 189,000